Pelvic floor muscle training versus other active treatments for urinary incontinence in women

Lins, Sabine; Hayder-Beichel, Daniela; Kunath, Frank; Cartwright, Rufus; Motschall, Edith; Antes, Gerd; Rücker, Gerta

doi:10.1002/14651858.cd007173.pub3

Cited by 5 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main purposes of PFMT are to improve strength of the pelvic organ support, as well as increase intraurethral pressure during effort thus, maximizing women's ability to maintain continence [Lins et al 2014]. A 2014 Cochrane review comparing 21 trials evaluating PFMT with no treatment for UI concluded that, overall, women who performed PFMT were 17 times more likely to report resolution or improvement of incontinence symptoms (RR 17.33, 95% CI: 4.31-69.64), have fewer urinary leakage episodes per day and have less leakage than controls [Hay-Smith et al 2011].…”

Section: Luts Managementmentioning

confidence: 99%

“…Pharmacological therapy is more commonly used for urgency UI and includes: anticholinergics, possibly vaginal estrogens in selected cases (and with patient’s informed consent), and more recently the use of botulinum toxin injection into the detrusor muscle. SRNI has also been indicated for stress UI [Lins et al . 2014].…”

Section: Luts Managementmentioning

confidence: 99%

“…2009] as first-line therapy in women with stress, urge, or mixed UI [Dumoulin and Hay-Smith, 2010]. The main purposes of PFMT are to improve strength of the pelvic organ support, as well as increase intraurethral pressure during effort thus, maximizing women’s ability to maintain continence [Lins et al . 2014].…”

Section: Pfmt Pelvic Floor Muscle Control Bladder Training and Behamentioning

confidence: 99%

See 2 more Smart Citations

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

et al. 2017

View full text Add to dashboard Cite

There is increasing attention and concern about managing the adverse effects of adjuvant endocrine therapy for women with early breast cancer as the side effects of therapy influence compliance and can impair quality of life (QoL). Most side effects associated with tamoxifen (TAM) and aromatase inhibitors (AIs) are directly related to estrogen deprivation, and the symptoms are similar to those experienced during natural menopause but appear to be more severe than that seen in the general population. Prolonged estrogen deprivation may lead to atrophy of the vulva, vagina, lower urinary tract and supporting pelvic structures, resulting in a range of genitourinary symptoms that can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of QoL. The genitourinary side effects may be prevented, reduced and managed in most cases but this requires early recognition and appropriate treatment. We provide an overview of practical clinical approaches to understanding the pathophysiology and the management of genitourinary symptoms in postmenopausal women receiving adjuvant endocrine therapy for breast cancer.

show abstract

Section: Luts Managementmentioning

confidence: 99%

Section: Luts Managementmentioning

confidence: 99%